Evidence map›Paper›PMID 40369880›Full record

ArticleInfluenza and other respiratory viruses2025

Low Levels of Neutralizing Antibodies Against SARS-CoV-2 KP.3.1.1 and XEC in Serum From Seniors in May 2024.

Even Fossum, Elisabeth Lea Vikse, Anna Hayman Robertson, Asia-Sophia Wolf, Andreas Rohringer, Lill Trogstad, Siri Mjaaland, Olav Hungnes, Karoline Bragstad

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Influenza and other respiratory viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Even FossumDepartment of Virology, Division of Infection Control, Norwegian Institute of Public Health, Oslo, Norway.ORCID 0000-0001-7064-0327
Elisabeth Lea VikseDepartment of Virology, Division of Infection Control, Norwegian Institute of Public Health, Oslo, Norway.
Anna Hayman RobertsonDepartment of Method Development and Analytics, Division of Infection Control, Norwegian Institute of Public Health, Oslo, Norway.ORCID 0000-0001-6295-0528
Asia-Sophia WolfDepartment of Method Development and Analytics, Division of Infection Control, Norwegian Institute of Public Health, Oslo, Norway.
Andreas RohringerDepartment of Virology, Division of Infection Control, Norwegian Institute of Public Health, Oslo, Norway.
Lill TrogstadDepartment of Method Development and Analytics, Division of Infection Control, Norwegian Institute of Public Health, Oslo, Norway.
Siri MjaalandDepartment of Method Development and Analytics, Division of Infection Control, Norwegian Institute of Public Health, Oslo, Norway.
Olav HungnesDepartment of Virology, Division of Infection Control, Norwegian Institute of Public Health, Oslo, Norway.
Karoline BragstadDepartment of Virology, Division of Infection Control, Norwegian Institute of Public Health, Oslo, Norway.ORCID 0000-0003-0943-0165

Funding

Norwegian Institute of Public Health
6 · The paper itself

Abstract

New immune evasive variants of SARS-CoV-2 may increase infections and hospitalizations in risk groups, such as the elderly. In this study, we evaluated neutralizing antibodies against KP.3.1.1 and XEC, virus variants that were either widely distributed or on the rise globally in the fall of 2024, in sera from a cohort of seniors aged 68-82 years collected in April/May 2024. Neutralizing responses were low against both KP.3.1.1 and XEC, also in XBB.1.5 boosted individuals and people with recent break-through infections, supporting the recommendation of an updated COVID-19 vaccine booster in this age group.

Indexed as

Antibodies, NeutralizingAntibodies, ViralCOVID-19SARS-CoV-2AgedAged, 80 and overCOVID-19 VaccinesFemaleHumansMaleAntibodies, NeutralizingAntibodies, ViralCOVID-19 VaccineselderlyimmunityKP.3.1.1neutralizing antibodiesSARS‐CoV‐2XEC

Identifiers

PMID40369880
PMCPMC12078752

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.